Form 4: Pfizer Executive Vice President Payal Sahni Reports Stock Transactions
SEC Form 4 Filing
Payal Sahni, Executive Vice President of Pfizer, reports the earn-out of stock appreciation rights and related transactions on February 27, 2025.
Summary
- On February 27, 2025, Payal Sahni, an Executive Vice President at Pfizer Inc., engaged in transactions involving Pfizer's common stock and stock appreciation rights.
- Sahni exercised stock appreciation rights, resulting in the acquisition of 19,054 shares at a price of $31.31.
- Shares were withheld to cover tax obligations (468 shares at $26.1) and the exercise price of the stock appreciation rights (17,846 shares at $26.06).
- Following these transactions, Sahni directly owns 25,928 shares of Pfizer common stock and indirectly owns 12,938 shares through a Rule 16b-3 plan.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reporting stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, as required by the SEC. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of earliest transaction: earn-out of stock appreciation rights, withholding of shares for tax obligations, and payment of exercise price. |
| 03/03/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.